Mucopolysaccharidosis Type VI clinical trials at University of California Health
3 in progress, 2 open to eligible people
In Utero Enzyme Replacement Therapy for Lysosomal Storage Diseases
open to eligible females ages 18-50
The investigators aims to determine the the maternal and fetal safety and feasibility of in utero fetal enzyme replacement therapy in fetuses with Lysosomal Storage Diseases.
at UCSF
Registry of Patients Diagnosed With Lysosomal Storage Diseases
open to eligible people ages up to 64 years
This is an international prospective and retrospective registry of patients with Lysosomal Storage Diseases (LSDs) to understand the natural history of the disease and the outcomes of fetal therapies, with the overall goal of improving the prenatal management of patients with LSDs.
at UCSF
Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI
Sorry, in progress, not accepting new patients
Randomized, double-blind, placebo-controlled, parallel-group, single-center study followed by open-label phase, to evaluate the effects of adalimumab compared to placebo on the change from baseline in joint and skeletal disease in children and adults with mucopolysaccharidosis (MPS) I, II or VI.
at UCLA
Our lead scientists for Mucopolysaccharidosis Type VI research studies include Lynda Polgreen, MD Tippi MacKenzie, MD.
Last updated: